We are developing medicines that can improve the lives of people with debiliating, neurological conditions. Our lead product candidate BTD-001, a small molecule GABA antagonist, is in development for the treatment of excessive daytime sleepiness in Idiopathic Hypersomnia and Narcolepsy Type 2 and for cognitive impairment in Down syndrome. We are also developing next generation products that share the pharmacological features of BTD-001 and may offer clinical advantages.




Phase 1

Phase 2

Phase 3

Rare Sleep Disorders
Idiopathic Hypersomnia BTD-001
Narcolepsy Type 2 BTD-001
Cognitive Impairment
Down Syndrome BTD-001
Rare Sleep Disorders Next Gen Analogs